OVERVIEW
The advent of immunotherapy has transformed dermatologic care, offering hope to patients with advanced NMSC. As the treatment armamentarium expands, clinicians must carefully weigh evolving data in order to optimize outcomes in BCC and CSCC.
Join us for this live webstream to hear our interprofessional expert panel offer privileged insights into evidence-based strategies for the identification of high-risk disease, selection of checkpoint inhibitors, and the management of immune-related adverse events. Uniquely, this panel discussion also features an experienced patient who will augment these insights with teaching moments from their treatment journey.
GOAL STATEMENT
This CE activity was designed to provide clinicians with strategies necessary for risk assessment, immunotherapy selection, and interprofessional collaboration to optimize outcomes in patients with advanced NMSC.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be better able to: [LIST] [ITEM]Identify high-risk patients with NMSC based on current staging systems, risk factors, and guidelines.[ITEM]Select appropriate checkpoint inhibitors in the management of patients with advanced NMSC. [ITEM]Integrate the unique roles and responsibilities of the interprofessional care team when managing patients with advanced NMSC.[/LIST]
ACCREDITATION STATEMENT
[JALOGO] In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
[bold]For Physicians[/bold] RMEI Medical Education, LLC designates this live activity for a maximum of 1.0 [italic]AMA PRA Category 1 Credit(s)™[/italic]. Physicians should claim only the credit commensurate with the extent of their participation in the activity. [bold]Interprofessional Continuing Education[/bold] [ICPE] This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI will disclose to learners the presence or absence of relevant financial relationships for all persons in control of content before the learner engages in the education
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Provided by RMEI Medical Education, LLC.